基于AHP法对广州市公园滨水植物景观评价

以广州市16个公园滨水植物景观实例作为研究对象,通过实地调查记录广州公园滨水植物材料的种类、景观特征、生态特征、种植方式、滨水植物景观空间特点,并应用层次分析法(AHP)对广州市主要公园滨水植物景观进行评价分析。结果表明,评判者打分导致评分偏高或偏低的主观影响较小,专家、专业学生和非专业学生三类人群对滨水植物景观的评分结果较为一致,有着相同趋势的审美取向。在景观类型上,与建筑小品结合式水景和可亲水式水景获好评比例相对较高。     

广州市道路绿地土壤肥力特征研究

通过对广州市12条道路绿地土壤进行采样调查,结合主成分分析法,研究广州市道路绿地土壤肥力特征及筛选出主导因子。结果表明,广州市道路绿地土壤pH值为5.52～8.76,碱性和强碱性土壤比例为78.26%;EC值和有机质平均值分别为0.19 mS/cm和26.52 g/kg;有效磷含量很高,全氮和全钾含量较高,全磷、碱解氮和速效钾含量较低。筛选结果显示,广州市道路绿地土壤pH值、有机质、全氮、全磷、碱解氮和有效磷可作为土壤肥力评价的主要因子,全钾和速效钾为次要因子。     

广州市城乡梯度森林公园雨季空气PM2.5浓度及水溶性离子特征

2012年雨季（4—9月）,收集广州市城市区、近郊区和远郊区森林公园的PM_2.5样品,测定PM_2.5质量浓度,分析了其中SO₄^2-、NO₃^-、NO₂^-、Cl^-、F^-、Na⁺、NH₄⁺、Ca²⁺、K⁺、Mg²⁺ 共10种水溶性无机离子含量.结果表明：帽峰山（远郊）、大夫山（近郊）、火炉山（城区）PM_2.5质量浓度的日变化分别为17.2～66.5、19.4～156.3、21.8～161.7 μg·m^-3,平均值分别为44.4、49.8、55.9 μg·m^-3.SO₄^2-、Na⁺和NH₄⁺为水溶性无机离子主要组分,其中,SO₄^2-含量最大,并从城区至郊区呈递减趋势.固定源对3个森林公园空气中SO₂和NO_x的贡献大于移动源,从城区至远郊呈递减趋势,说明机动车对城区空气中SO₂和NO_x的贡献大于近郊和远郊森林公园.采样期间,海盐对大夫山空气PM_2.5中水溶性组分的贡献最大,其中K⁺受海盐的影响超过其他元素.NH₄⁺当量浓度远小于SO₄^2-和NO₃^-的当量浓度,中和度远小于1,反映PM_2.5酸性较强,且从远郊至城区PM_2.5粒子酸性呈增强趋势.     

广州市中心城区公园鸟类多样性及季节动态

1999年1月—2000年4月和2006年7月—2007年6月,用路线法对广州市中心城区5个公园的鸟类组成及多样性进行了调查,共记录到鸟类64种。暗绿绣眼鸟(Zosterops japonica)、白头鹎(Pycnonotus sinensis)和夜鹭(Nycticorax nyctinorax)是优势种。留鸟、冬候鸟和夏候鸟分别占鸟类种数的64.1%、26.6%和7.8%。以9月份记录到的鸟种最多(31种)、7月份和11月份记录到的鸟种最少(均为20种)。公园鸟类的平均遇见率为[(65±5)ind./h],3月份鸟的遇见率最高[(98±29)ind./h],1月份鸟的遇见率最低[(35±11)ind./h],但各月鸟类的遇见率无显著性差异(F3,56=1.35,P=0.226)。在4、9和12月,迁徙鸟种类最多,迁徙鸟遇见率季节变化明显(F11,48=3.098,P=0.003)。各公园鸟类的丰度不同,鸟种数与公园总面积显著相关(R=0.905,P=0.035;S=11.02A0.28,S:鸟类种数,A:公园总面积),即鸟种的数量随公园面积的增大而增加。从鸟类多样性保护和城市用地的角度考虑,广州市公园面积在65hm2左右较佳。     

BiHC,a T-Cell–Engaging Bispecific Recombinant Antibody,Has Potent Cytotoxic Activity Against Her2 Tumor Cells

Among different cancer immunotherapy approaches, bispecific antibodies (BsAbs) are of great interest due to their ability to recruit immune cells to kill tumor cells directly. Various BsAbs against Her2 tumor cells have been proposed with potent cytotoxic activities. However, most of these formats require extensive processing to obtain heterodimeric bispecific antibodies. In this study, we describe a bispecific antibody, BiHC (bispecific Her2-CD3 antibody), constructed with a single-domain anti-Her2 and a single-chain Fv (variable fragment) of anti-CD3 in an IgG-like format. In contrast to most IgG-like BsAbs, the two arms in BiHC have different molecular weights, making it easier to separate hetero- or homodimers. BiHC can be expressed in Escherichia coli and purified via Protein A affinity chromatography. The purified BiHC can recruit T cells and induce specific cytotoxicity of Her2-expressing tumor cells in vitro. The BiHC can also efficiently inhibit the tumor growth in vivo. Thus, BiHC is a promising candidate for the treatment of Her2-positive cancers.     

Clinical Features of Brain Metastases in Small Cell Lung Cancer: an Implication for Hippocampal Sparing Whole Brain Radiation Therapy

PURPOSE: To assess the clinical features and distribution of brain metastases (BMs) of small cell lung cancer (SCLC) in the hippocampal and perihippocampal region, with the purpose of exploring the viability of hippocampal-sparing whole-brain radiation therapy (HS-WBRT) on reducing neurocognitive deficits. METHODS: This was a retrospective analysis of the clinical characteristics and patterns of BMs in patients with SCLC. Associations between the clinical characteristics and hippocampal metastases (HMs)/perihippocampal metastases (PHMs) were evaluated in univariate and multivariate regression analyses. RESULTS: A total of 1594 brain metastatic lesions were identified in 180 patients. Thirty-two (17.8%) patients were diagnosed with BMs at the time of primary SCLC diagnosis. The median interval between diagnosis of primary SCLC and BMs was 9.3 months. There were 9 (5.0%) and 22 (12.2%) patients with HMs and PHMs (patients with BMs located in or within 5 mm around the hippocampus), respectively. In the univariate and multivariate analysis, the number of BMs was the risk factor for HMs and PHMs. Patients with BMs ≥ 5 had significantly higher risk of HMs (odds ratio [OR] 7.892, 95% confidence interval [CI] 1.469-42.404, P = .016), and patients with BMs ≥ 7 had significantly higher risk of PHMs (OR 5.162, 95% CI 2.017-13.213, P = .001). Patients with extracranial metastases are also associated with HMs. CONCLUSIONS: Our results indicate that patients with nonoligometastatic disease are significantly associated with HMs and PHMs. The incidence of PHMs may be acceptably low enough to perform HS-WBRT for SCLC. Our findings provide valuable clinical data to assess the benefit of HS-WBRT in SCLC patients with BMs.     

RYBP Inhibits Progression and Metastasis of Lung Cancer by Suppressing EGFR Signaling and Epithelial-Mesenchymal Transition

Lung cancer (LC) is a common lethal malignancy with rapid progression and metastasis, and Ring1 and YY1 binding protein (RYBP) has been shown to suppress cell growth in human cancers. This study aimed to investigate the role of RYBP in LC progression and metastasis. In this study, a total of 149 LC patients were recruited, and the clinical stage of their tumors, metastasis status, survival time, presence of epidermal growth factor receptor (EGFR) mutation, and RYBP expression levels were measured. RYBP silencing and overexpression were experimentally performed in LC cell lines and in nude mice, and the expressions of genes in EGFR-related signaling pathways and epithelial-mesenchymal transition (EMT) were detected. The results showed that RYBP was downregulated in LC compared with adjacent normal tissues, and low RYBP expression was associated with a more severe clinical stage, high mortality, high metastasis risk, and poor survival. Cell proliferation and xenograft growth were inhibited by RYBP overexpression, whereas proliferation and xenograft growth were accelerated by RYBP silencing. EGFR and phosphorylated-EGFR levels were upregulated when RYBP was silenced, whereas EGFR, p-EGFR, p-AKT, and p-ERK were downregulated when RYBP was overexpressed. Low RYBP expression was related to a high metastasis risk, and metastasized tumors showed low RYBP levels. Cell migration and invasion were promoted by silencing RYBP but were inhibited by overexpressed RYBP. In addition, the EMT marker vimentin showed diminished expression, and E-cadherin was promoted by the overexpression of RYBP. In conclusion, our data suggest that RYBP suppresses cell proliferation and LC progression by impeding the EGFR-ERK and EGFR-AKT signaling pathways and thereby inhibiting cell migration and invasion and LC metastasis through the suppression of EMT.     

The Effect of Adding Neoadjuvant Chemotherapy to Concurrent Chemoradiotherapy in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma and Undetectable Pretreatment Epstein-Barr Virus DNA

PURPOSE: To assess the effect of adding neoadjuvant chemotherapy (NACT) to concurrent chemoradiotherapy (CCRT) in patients with locoregionally advanced nasopharyngeal carcinoma (NPC) and undetectable pretreatment Epstein-Barr virus (pEBV) DNA. MATERIALS AND METHODS: We enrolled 639 NPC patients with stage II to IVB and undetectable pEBV DNA to receive CCRT with or without NACT. Radiotherapy was 2.0 to 2.27 Gy per fraction with five daily fractions per week for 6 to 7 weeks to the primary tumor and 62 to 70 Gy to the involved neck area. NACT was cisplatin (80-100 mg/m² day 1) and 5-fluorouracil (800-1000 mg/m², 120-hour continuous intravenous infusion) every 3 weeks for two or three cycles. CCRT was cisplatin (80-100 mg/m² day 1) every 3 weeks for three cycles. RESULTS: For all patients, the 5-year overall survival (OS), locoregional relapse-free survival (LRFS), distant metastasis-free survival (DMFS), and progression-free survival (PFS) rates were 91.9%, 92.2%, 95.0%, and 86.4%, respectively. There was no significant difference in OS (5-year OS 90.8% [NACT + CCRT group] vs 92.7% [CCRT alone]; hazard ratio [HR] 1.24; P = .486), LRFS (HR 1.13, 95% confidence interval [CI] 0.59-2.14, P = .715), DMFS (HR 0.78, 95% CI 0.34-1.78, P = .554), or PFS (HR 1.21, 95% CI 0.75-1.95, P = .472). CONCLUSION: CCRT with or without NACT produced a good treatment outcome in patients with locoregionally advanced NPC and undetectable pEBV DNA, but NACT before CCRT did not significantly improve survival rates.     

Impact of Serum Apolipoprotein A-I on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer: a Propensity Score-Matched Analysis

PURPOSE: We aimed to investigate the role of apolipoprotein A-I (ApoA-I) as a predictor of prognosis and treatment efficacy of bevacizumab in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without bevacizumab. METHODS: We conducted a retrospective study on consecutive patients who were diagnosed with mCRC at Sun Yat-sen University Cancer Center. According to their pretreatment ApoA-I level, patients were divided into low– and high–ApoA-I groups. Propensity score-matched method was performed to balance baseline characteristics between two groups. Based on whether they accepted bevacizumab as a first-line therapy, patients were further divided into the chemo + bevacizumab group and the chemo group. Overall survival (OS) and progression-free survival (PFS) were assessed with Kaplan-Meier method, log-rank test, and Cox regression. RESULTS: The optimal cutoff value for the ApoA-I level was determined to be 1.105 g/l. In the propensity-matched cohort of 508 patients, low ApoA-I was significantly associated with inferior OS (P < .001) and PFS (P < .001) than high ApoA-I. Multivariate analysis showed that ApoA-I level was an independent prognostic maker of OS (P < .001) and PFS (P = .001). PFS (P < .001) in either the high– or low–ApoA-I groups could be extended significantly after the administration of bevacizumab, and patients with a high ApoA-I level also had a better OS in the chemo + bevacizumab group than the chemo group (P = .049). CONCLUSIONS: Patients with a low ApoA-I level have poor prognoses, and they did not display an OS benefit from bevacizumab.     

广州大学城绿地应用树种结构分析

根据实地踏查和文献资料详细调查广州大学城城市绿地的总体布局, 各类绿地的树种结构和组成。调查发现,大学城道路绿化率高达90%,行道树应用树种有70种,隶属于29科;附属绿地树木有122种,包含42科106属。结合道路和各单位附属绿地的树木种类及其出现频率,进一步分析大学城城市森林的树木配置和美学价值,并针对绿化树种存在问题提出改善建议。